Show simple item record

dc.contributor.authorAltowati, MAen_US
dc.contributor.authorJones, APen_US
dc.contributor.authorHickey, Hen_US
dc.contributor.authorWilliamson, PRen_US
dc.contributor.authorBarakat, FMen_US
dc.contributor.authorPlaatjies, NCen_US
dc.contributor.authorHardwick, Ben_US
dc.contributor.authorRussell, RKen_US
dc.contributor.authorJaki, Ten_US
dc.contributor.authorAhmed, SFen_US
dc.contributor.authorSanderson, IRen_US
dc.date.accessioned2016-12-12T10:20:48Z
dc.date.available2016-11-21en_US
dc.date.issued2016en_US
dc.date.submitted2016-12-07T11:55:36.150Z
dc.identifier.issn2055-5784en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/18182
dc.description.abstractBACKGROUND: Despite optimal therapy, many children with Crohn's disease (CD) experience growth retardation. The objectives of the study are to assess the feasibility of a randomised control trial (RCT) of injectable forms of growth-promoting therapy and to survey the attitudes of children with CD and their parents to it. METHODS: A feasibility study was carried out to determine study arms, sample size and numbers of eligible patients. A face-to-face questionnaire surveyed willingness to consent to future participation in the RCT. Eligibility to the survey was any child under 18 (with their parent/guardian) with CD whose height standard deviation score (HtSDS) was ≤+1. Of 118 questionnaires, 94 (80%) were returned (48 by children and 46 by parents). RESULTS: The median age of the patients in the survey was 14.3 years (range 7.0 to 17.7), and 35 (73%) were male. Their median HtSDS was -1.2 (-3.01, 0.23), and it was lower than the median mid-parental HtSDS of -0.6 (-3.1, 1.4). We analysed the willingness of the children whose HtSDS <-1 to take part in the proposed RCT, being those most likely to require treatment. Overall, 18 (47%) children and 17 (46%) parents were willing. This increased to 61% of children who were slightly concerned about their height and 100% (4/4) of those very concerned. A common reason for not taking part in the RCT was fear of injections (44%); 111 children are required for randomisation into three study arms from nine centres. CONCLUSIONS: Almost half of children and parents surveyed would take part in an RCT of growth-promoting therapy. Allaying fears about injections may result in higher recruitment rates.en_US
dc.description.sponsorshipThis study was supported by funding from Crohn’s in Childhood Research Association (CICRA). MA is funded by the Higher Education Ministry of Libyan Government for a postgraduate studentship. RR is supported by a NHS Research Scotland career fellowship award and has received support from a Medical Research Council (MRC) patient research cohort initiative grant (G0800675) for PICTS. The work of the IBD team at the Royal Hospital for Sick Children is supported by the Catherine McEwan Foundation and the Yorkhill IBD funden_US
dc.format.extent71 - ?en_US
dc.languageengen_US
dc.relation.ispartofPilot Feasibility Studen_US
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.subjectCrohn’s diseaseen_US
dc.subjectGrowth hormoneen_US
dc.subjectGrowth retardationen_US
dc.subjectInflammatory bowel diseaseen_US
dc.subjectInsulin-like growth factor-1en_US
dc.subjectPubertyen_US
dc.titleAssessing the feasibility of injectable growth-promoting therapy in Crohn's disease.en_US
dc.typeArticle
dc.rights.holder© The Author(s), 2016.
dc.identifier.doi10.1186/s40814-016-0112-9en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/27965886en_US
pubs.notesNot knownen_US
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute/Immunobiology
pubs.organisational-group/Queen Mary University of London/REF
pubs.organisational-group/Queen Mary University of London/REF/REF - Blizard
pubs.publication-statusPublished onlineen_US
pubs.volume2en_US
dcterms.dateAccepted2016-11-21en_US
qmul.funderMulti-centre feasibility study on the efficacy of insulin-like growth factor-1 and growth hormone in children with Crohn's disease-induced growth failure::Crohn's in Childhood Research Association (CICRA)en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record